---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-24-006382"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2024-09-20T23:59:59+00:00"
generated_at: "2026-05-31T02:48:13.984080+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials

## Summary
- Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.
- Partnered with Exotropin to develop topical aesthetic and anti-aging products using exosome technology; holds minority stake.
- Changed name from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024 to reflect scientific focus.
- Regenerative medicine market projected to grow to $175B by 2032 at 22.8% CAGR, per Precedence Research.

## SEC filing metadata
- accession: 0001829126-24-006382
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2024-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/0001829126-24-006382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-24-006382
- JSON: https://secwatch.observer/filing/0001829126-24-006382.json
- Plain text: https://secwatch.observer/filing/0001829126-24-006382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.